Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

Well, it makes sense insofar as the amount to be raised greatly exceeds the capacity of the new ATM.

This offering may be a signal that MNTA expects to lose the Lovenox patent case and thereby have to forfeit at least $35M in damages to Amphastar.